BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 Q2 P&L / Income Statement

BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

5,442,000,000 US dollars

Cost of products sold (excluding amortization expense)

1,594,000,000 US dollars

Gross profit

3,848,000,000 US dollars

Operating expenses

2,670,000,000 US dollars

Operating income (loss)

1,178,000,000 US dollars

Other income (expense), net (calculated)

negative 118,000,000 US dollars

Income (loss) before income taxes

1,060,000,000 US dollars

Income tax expense (benefit)

155,000,000 US dollars

Net income (loss)

905,000,000 US dollars

Cardiac Rhythm Management - UNITED STATES

349,000,000 US dollars

Cardiac Rhythm Management - Int'l

236,000,000 US dollars

Electrophysiology - UNITED STATES

606,000,000 US dollars

Electrophysiology - Int'l

310,000,000 US dollars

Endoscopy - UNITED STATES

491,000,000 US dollars

Endoscopy - Int'l

303,000,000 US dollars

Neuromodulation - UNITED STATES

257,000,000 US dollars

Neuromodulation - Int'l

84,000,000 US dollars

Urology - UNITED STATES

503,000,000 US dollars

Urology - Int'l

181,000,000 US dollars

Interventional Cardiology & Vascular Therapies - UNITED STATES

586,000,000 US dollars

Interventional Cardiology & Vascular Therapies - Int'l

746,000,000 US dollars

Interventional Oncology & Embolization - UNITED STATES

175,000,000 US dollars

Interventional Oncology & Embolization - Int'l

108,000,000 US dollars

Watchman - UNITED STATES

459,000,000 US dollars

Watchman - Int'l

48,000,000 US dollars

Selling, general and administrative expenses

1,803,000,000 US dollars

Research and development expenses

554,000,000 US dollars

Royalty expense

12,000,000 US dollars

Amortization expense

233,000,000 US dollars

Intangible asset impairment charges

0 US dollars

Contingent consideration net expense (benefit)

negative 16,000,000 US dollars

Restructuring net charges (credits)

8,000,000 US dollars

Litigation-related net charges (credits)

76,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to BOSTON SCIENTIFIC CORPORATION: $907.00 M; to noncontrolling interests: −$2.00 M.